Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib vs Platinum-Based Chemotherapy in Adjuvant ALK-Positive NSCLC
NCT03456076Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2018
- Primary completion
- Jun 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 27
01
Overview
A Phase 3 trial of alectinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Aug 2018; status: active, not recruiting.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03456076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456076.